TABLE 3.

SBA GMTs by target straina

Strain and timecTrL3-4aTrL3-8aTrL-8nL7-8aL7-8nVAMen
nbGMT (95% CI)nGMT (95% CI)nGMT (95% CI)nGMT (95% CI)nGMT (95% CI)nGMT (95% CI)
H44-76
    Pre2012.4 (7.8-19.7)1711.6 (6.8-19.9)1515.8 (9.2-26.9)2314.9 (9.9-22.4)1917.5 (9.5-32.3)1818.4 (10.1-33.5)
    Post II2118.2 (13.1-25.3)1817.8 (12.8-24.8)1826.3 (17.0-40.8)2327.4 (17.7-42.4)1934.6 (18.6-64.3)1749.1 (24.7-97.7)
    Post III2123.6 (15.6-35.8)1822.7 (16.1-32.0)1635.6 (19.9-63.8)2237.9 (23.9-60.1)1952.9 (27.5-101.6)1592.7 (37.8-227.6)
NZ98/124
    Pre2046.1 (30.4-69.9)1671.6 (45.2-113.2)1859.6 (39.6-89.6)2247.2 (30.1-74.0)1860.3 (35.6-102.0)1779.7 (46.8-135.9)
    Post II2061.0 (40.8-91.2)1878.2 (54.1-113.1)1866.2 (47.1-93.1)2354.3 (39.9-73.9)1961.3 (42.0-89.6)16113.9 (67.0-193.6)
    Post III2153.2 (35.9-78.9)1795.9 (69.3-132.6)1667.1 (42.8-105.2)2388.7 (60.7-129.6)1983.0 (51.3-134.2)14140.7 (62.4-317.3)
760676
    Pre203.5 (1.9-6.4)187.8 (3.2-19.2)162.9 (1.2-6.6)224.8 (2.5-9.4)182.8 (1.4-5.6)185.1 (2.4-10.8)
    Post II203.1 (1.8-5.5)186.2 (2.5-15.1)171.5 (0.9-2.5)235.2 (2.4-11.2)193.9 (1.9-8.0)1819.4 (10.9-34.5)
    Post III213.6 (2.2-5.9)178.8 (3.6-21.4)153.0 (1.4-6.4)236.2 (3.0-12.9)194.2 (2.2-7.8)1735.1 (19.9-61.9)
  • a For study group compositions, see Table 1.

  • b Number of subjects whose antibody titers were available.

  • c Pre, prior to vaccination; Post II, 1 month after second vaccination; Post III, 1 month after third vaccination.